Literature DB >> 18334793

NPHS2 mutations.

Ashraf Bakr1, Soheir Yehia, Doaa El-Ghannam, Ayman Hammad, Mohamed Ragab, Amr Sarhan, Fatma Al-Husseni, Zakaria Al-Morsy.   

Abstract

OBJECTIVE: To uncover the frequency and the spectrum of NPHS2 mutations in Egyptian children with non familial steroid-resistant nephrotic syndrome (SRNS).
METHODS: Sixteen patients were screened by PCR-single-strand conformation polymorphism analysis of NPHS2 gene followed by direct sequencing.
RESULTS: NPHS2 mutations were evident in four patients (25%) who were bearing four novel mutations including two frame shift mutations (R238fs and P45fs) and two missense mutations (I136L and F216Y). There were no phenotypic or histological characteristics of patients bearing NPHS2 mutations, apart from the earlier onset of the disease, compared to those who were not bearing mutations.
CONCLUSION: NPHS2 mutations are prevalent in Egyptian children with non-familial SRNS and this may in part explain the less favorable prognosis reported in these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334793     DOI: 10.1007/s12098-008-0020-y

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  9 in total

1.  Fast and sensitive silver staining of DNA in polyacrylamide gels.

Authors:  B J Bassam; G Caetano-Anollés; P M Gresshoff
Journal:  Anal Biochem       Date:  1991-07       Impact factor: 3.365

2.  Mutations in NPHS2 encoding podocin are a prevalent cause of steroid-resistant nephrotic syndrome among Israeli-Arab children.

Authors:  Yaacov Frishberg; Choni Rinat; Orli Megged; Eli Shapira; Sofia Feinstein; Annick Raas-Rothschild
Journal:  J Am Soc Nephrol       Date:  2002-02       Impact factor: 10.121

Review 3.  NPHS2 (Podocin) mutations in nephrotic syndrome. Clinical spectrum and fine mechanisms.

Authors:  Gianluca Caridi; Francesco Perfumo; Gian Marco Ghiggeri
Journal:  Pediatr Res       Date:  2005-04-06       Impact factor: 3.756

4.  Analysis of NPHS2 mutations in Turkish steroid-resistant nephrotic syndrome patients.

Authors:  Z Birsin Ozçakar; F Başak Cengiz; Nilgün Cakar; Nermin Uncu; Nazli Kara; Banu Acar; Selçuk Yüksel; Mesiha Ekim; Mustafa Tekin; Fatoş Yalçinkaya
Journal:  Pediatr Nephrol       Date:  2006-06-30       Impact factor: 3.714

5.  NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome.

Authors:  N Boute; O Gribouval; S Roselli; F Benessy; H Lee; A Fuchshuber; K Dahan; M C Gubler; P Niaudet; C Antignac
Journal:  Nat Genet       Date:  2000-04       Impact factor: 38.330

6.  Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin.

Authors:  K Schwarz; M Simons; J Reiser; M A Saleem; C Faul; W Kriz; A S Shaw; L B Holzman; P Mundel
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

7.  Interaction with podocin facilitates nephrin signaling.

Authors:  T B Huber; M Kottgen; B Schilling; G Walz; T Benzing
Journal:  J Biol Chem       Date:  2001-09-18       Impact factor: 5.157

8.  NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence.

Authors:  Stefanie Weber; Olivier Gribouval; Ernie L Esquivel; Vincent Morinière; Marie-Josèphe Tête; Christophe Legendre; Patrick Niaudet; Corinne Antignac
Journal:  Kidney Int       Date:  2004-08       Impact factor: 10.612

9.  Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome.

Authors:  Rainer G Ruf; Anne Lichtenberger; Stephanie M Karle; Johannes P Haas; Franzisco E Anacleto; Michael Schultheiss; Isabella Zalewski; Anita Imm; Eva-Maria Ruf; Bettina Mucha; Arvind Bagga; Thomas Neuhaus; Arno Fuchshuber; Aysin Bakkaloglu; Friedhelm Hildebrandt
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

  9 in total
  1 in total

1.  Rituximab for refractory cases of childhood nephrotic syndrome.

Authors:  Jameela A Kari; Salah M El-Morshedy; Sherif El-Desoky; Hammad O Alshaya; Khawla A Rahim; Burhan M Edrees
Journal:  Pediatr Nephrol       Date:  2011-01-31       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.